smac mimetics antagonize ciap1 2 (Mimetics)
Structured Review
Smac Mimetics Antagonize Ciap1 2, supplied by Mimetics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ciap1+2/mimetics+smac/pm41531664-235-0-1
Average 86 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: Reprogramming gut microenvironment for the treatment of acute severe ulcerative colitis via a synergistic therapy of necroptosis blockade and organoid transplantation. Article Snippet: HeLa cells were treated with 20 ng/ml TNFα, 1 μM Article Title: Species-specific cleavage of the autophagy adaptor p62 dictates responses to TNF. Article Snippet: Characterization of Article Title: Reprogramming gut microenvironment for the treatment of acute severe ulcerative colitis via a synergistic therapy of necroptosis blockade and organoid transplantation. Article Snippet: For TSZ stimulation, HT-29 cells and colonic organoids were treated with 10 ng/ml TNFα, 1 μM Article Title: The Role of Mitochondria in Polycystic Kidney Disease. Article Snippet: Other studies showed that second mitochondriaderived activator of Article Title: Defensin‐DNA Supramolecular Complexes as a New pH‐Sensing Nanomaterial Article Snippet: Zebrafish embryos were imaged as previously described using an Andor Dragonfly 202 spinning-disk confocal microscope (Andor Technology, Oxford Instruments, Belfast, UK) [ 38 ]. Article Title: PD-1/PD-L1 inhibitors Article Snippet: In another specific embodiment, a compound disclosed herein, or a pharmaceutically acceptable salt thereof, is combined with an HBV DNA polymerase inhibitor and at least one additional therapeutic agent selected from the group consisting of: immunomodulators, TLR modulators, interferon alpha receptor ligands, hyaluronidase inhibitors, recombinant IL-7, HBsAg inhibitors, HBsAg secretion or assembly inhibitors, compounds targeting HBcAg, cyclophilin inhibitors, HBV vaccines, HBV viral entry inhibitors, NTCP inhibitors, antisense oligonucleotide targeting viral mRNA, siRNA, miRNA gene therapy agents, endonuclease modulators, inhibitors of ribonucleotide reductase, hepatitis B virus E antigen inhibitors, recombinant SRA proteins, src kinase inhibitors, HBx inhibitors, cccDNA inhibitors, sshRNAs, HBV antibodies including HBV antibodies targeting the surface antigens of the hepatitis B virus and bispecific antibodies and “antibody-like” therapeutic proteins (such as DARTs®, DUOBODIES®, BITES®, XmAbs®, TandAbs, Fab derivatives, or TCR-like antibodies), CCR2 chemokine antagonists, thymosin agonists, cytokines, nucleoprotein modulators (HBV core or capsid protein modulators), stimulators of retinoic acid-inducible gene 1, stimulators of RIG-I like receptors, stimulators of NOD2, stimulators of NOD1, Arginase inhibitors, STING agonists, PI3K inhibitors, lymphotoxin beta receptor activators, natural killer cell receptor 2B4 inhibitors, Lymphocyte-activation gene 3 inhibitors, CD160 inhibitors, cytotoxic T-lymphocyte-associated protein 4 (ipi4) inhibitors, CD137 inhibitors, Killer cell lectin-like receptor subfamily G member 1 inhibitors, TIM-3 inhibitors, B- and T-lymphocyte attenuator inhibitors, CD305 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PEG-Interferon Lambda, recombinant thymosin alpha-1, BTK inhibitors, modulators of TIGIT, modulators of CD47, modulators of SIRPalpha, modulators of ICOS, modulators of CD27, modulators of CD70, modulators of OX40, epigenetic modifiers, modulators of NKG2D, modulators of Tim-4, modulators of B7-H4, modulators of B7-H3, modulators of NKG2A, modulators of GITR, modulators of CD160, modulators of HEVEM, modulators of CD161, modulators of Axl, modulators of Mer, modulators of Tyro, gene modifiers or editors such as CRISPR (including CRISPR Cas9), zinc finger nucleases or synthetic nucleases (TALENs), IAPs inhibitors, In Vitro:Article Title: To Kill a Macrophage: Targeted Strategies to Eliminate Macrophage Reservoirs of HIV Article Snippet: .. Inhibition:Article Title: Ferroptosis, pyroptosis, and necroptosis in melanoma: regulatory cell death pathways and their implications for immunotherapy Article Snippet: .. Necroptosis , RIPK1/RIPK/MLKL Axis; TNF-α Inhibition; Epigenetic Silencing of RIPK3 , RIPK3; p-MLKL; HMGB1 , 5-Azacytidine; Vorinostat; |
